Adjuvant Lipoic acid Injection in Sepsis treatment in China (ALIS study): protocol for a randomised, single-blind, placebo-controlled trial
Open Access
Abstract
Introduction Sepsis is a life-threatening immune disorder resulting from an dysregulated host response to infection. Adjuvant therapy is a valuable complement to sepsis treatment. Lipoic acid has shown potential in attenuating sepsis-induced immune dysfunction and organ injury in vivo and in vitro studies. However, clinical evidence of lipoic acid injection in sepsis treatment is lacking. Hence, we devised a randomised controlled trial to evaluate the efficacy and safety of lipoic acid injection in improving the prognosis of sepsis or septic shock patients. Methods and analysis A total of 352 sepsis patients are planned to be recruited from intensive care units (ICUs) at eight tertiary hospitals in China for this trial. Eligible participants will undergo randomisation in a 1:1 ratio, allocating them to either the control group or the experimental group. Both groups received routine care, with the experimental group also receiving lipoic acid injection and the control group receiving placebo. The primary efficacy endpoint is 28-day all-cause mortality. The secondary efficacy endpoints are as follows: ICU and hospital mortality, ICU and hospital stay, new acute kidney injury in ICU, demand and duration of life support, Sequential Organ Failure Assessment (SOFA)/Acute Physiology and Chronic Health Evaluation II (APACHE II) and changes from baseline (ΔSOFA/ΔApache II), arterial blood lactate (LAC) and changes from baseline (ΔLAC), blood procalcitonin, high-sensitivity C-reactive protein, interleukin-2 (IL-2), IL-4, IL-6, IL-10, tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) and changes from baseline on day 1 (D1), D3, D5 and D7. Clinical safety will be assessed through analysis of adverse events. Ethics and dissemination The study was approved by the Ethics Committee of Maoming People’s Hospital (approval no. PJ2020MI-019-01). Informed consent will be obtained from the participants or representatives. The findings will be disseminated through academic conferences or journal publications. Trial registration ChiCTR2000039023.Keywords
Funding Information
- Major program of Summit Project, Guangdong Province High-level Hospital Construction Project of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences (DFJH2020028)
- Guangzhou Science and Technology Program (201803010058)
- High-level Hospital Construction Research Project of Maoming People's Hospital (zx2020017)
- National Natural Science Foundation of China (82172162)
- Special Science and Technology Fund of Maoming City (2021KJZXZJYX003)
- Medical Research Fund of Guangdong province (B2022246)
- Excellent Young Talents Project of Maoming People's Hospital (SY2021005)
- Emergent Science and Technology Project for Prevention and Treatment of Novel Coronavirus Pneumonia (2020YJ01)
- Office of Talent Work Leading Team in Maoming (MaoRenCaiBan [2020]24)
This publication has 63 references indexed in Scilit:
- Critical care and the global burden of critical illness in adultsThe Lancet, 2010
- α-LIPOIC ACID AS A POTENTIAL TARGET FOR THE TREATMENT OF LUNG INJURY CAUSED BY CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS MODEL IN RATSShock, 2010
- Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potentialBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2008
- α-Lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathwayProceedings of the National Academy of Sciences, 2007
- Phosphorylation of Endothelial Nitric-Oxide Synthase Is Diminished in Mesenteric Arteries from Septic Rabbits Depending on the Altered Phosphatidylinositol 3-Kinase/Akt Pathway: Reversal Effect of Fluvastatin TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Role of phosphatidylinositol 3-kinase-γ in mediating lung neutrophil sequestration and vascular injury induced byE. colisepsisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic SyndromeCirculation, 2005
- α-Lipoic Acid Inhibits Endotoxin-stimulated Expression of iNOS and Nitric Oxide Independent of the Heat Shock Response in RAW 264.7 CellsFree Radical Research, 2004
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003